FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100502483> ?p ?o ?g. }

• W3100502483 endingPage "888" @default.
• W3100502483 startingPage "877" @default.
• W3100502483 abstract "Purpose To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB) therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB. Clinical Relevance The primary concern regarding IVB treatment of ROP is the potential systemic side effects, especially the risk of causing severe neurodevelopmental impairment (sNDI). Results regarding neurodevelopmental outcomes after IVB therapy are conflicting. Methods We conducted a meta-analysis and searched PubMed, Embase, and Web of Science for related publications from inception through March 12, 2020. The eligibility criteria were as follows: comparative studies of ROP patients that (1) included IVB as a treatment arm, (2) included a control group without bevacizumab treatment, and (3) reported on at least 1 neurodevelopmental outcome, such as sNDI, Bayley Scales of Infant and Toddler Development, Third Edition (Bayley III), composition scores, or cerebral palsy (CP). The primary outcome was sNDI, with the odds ratio (OR) calculated. Secondary outcomes were mean differences (MDs) for cognitive, language, and motor scores (Bayley III) and OR for CP. The quality of evidence was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation approach. Results Eight studies, 6 including laser-controlled ROP infants and 2 including ROP infants not requiring treatment, were included. The weighted OR for sNDI in the IVB group was 1.39 (95% confidence interval [CI], 0.98–1.97). The weighted MDs were –1.92 (95% CI, –4.73 to 0.88), –1.32 (95% CI, –4.65 to 1.99), and –3.66 (95% CI, –6.79 to –0.54) for cognitive, language, and motor scores in Bayley III, respectively. The OR for CP was 1.20 (95% CI, 0.56–2.55). No differences were observed between the preset subgroups comprising laser-controlled ROP infants and ROP infants not requiring treatment. The current quality of evidence was rated as low (sNDI and all Bayley III scores) to very low (CP). Conclusions Risk of sNDI was not increased in ROP patients after IVB treatment. Bayley III scores were similar in the IVB and control groups, except for a minor difference in motor performance. These findings suggest that the risk of additional sNDI after IVB treatment is low. Randomized trials are warranted to provide a higher quality of evidence. To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB) therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB. The primary concern regarding IVB treatment of ROP is the potential systemic side effects, especially the risk of causing severe neurodevelopmental impairment (sNDI). Results regarding neurodevelopmental outcomes after IVB therapy are conflicting. We conducted a meta-analysis and searched PubMed, Embase, and Web of Science for related publications from inception through March 12, 2020. The eligibility criteria were as follows: comparative studies of ROP patients that (1) included IVB as a treatment arm, (2) included a control group without bevacizumab treatment, and (3) reported on at least 1 neurodevelopmental outcome, such as sNDI, Bayley Scales of Infant and Toddler Development, Third Edition (Bayley III), composition scores, or cerebral palsy (CP). The primary outcome was sNDI, with the odds ratio (OR) calculated. Secondary outcomes were mean differences (MDs) for cognitive, language, and motor scores (Bayley III) and OR for CP. The quality of evidence was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation approach. Eight studies, 6 including laser-controlled ROP infants and 2 including ROP infants not requiring treatment, were included. The weighted OR for sNDI in the IVB group was 1.39 (95% confidence interval [CI], 0.98–1.97). The weighted MDs were –1.92 (95% CI, –4.73 to 0.88), –1.32 (95% CI, –4.65 to 1.99), and –3.66 (95% CI, –6.79 to –0.54) for cognitive, language, and motor scores in Bayley III, respectively. The OR for CP was 1.20 (95% CI, 0.56–2.55). No differences were observed between the preset subgroups comprising laser-controlled ROP infants and ROP infants not requiring treatment. The current quality of evidence was rated as low (sNDI and all Bayley III scores) to very low (CP). Risk of sNDI was not increased in ROP patients after IVB treatment. Bayley III scores were similar in the IVB and control groups, except for a minor difference in motor performance. These findings suggest that the risk of additional sNDI after IVB treatment is low. Randomized trials are warranted to provide a higher quality of evidence." @default.
• W3100502483 created "2020-11-23" @default.
• W3100502483 creator A5003368090 @default.
• W3100502483 creator A5014220089 @default.
• W3100502483 creator A5017169978 @default.
• W3100502483 creator A5018228875 @default.
• W3100502483 creator A5040903099 @default.
• W3100502483 creator A5057095268 @default.
• W3100502483 date "2021-06-01" @default.
• W3100502483 modified "2023-10-10" @default.
• W3100502483 title "Neurodevelopmental Outcomes after Bevacizumab Treatment for Retinopathy of Prematurity" @default.
• W3100502483 cites W1531891274 @default.
• W3100502483 cites W1957871175 @default.
• W3100502483 cites W1970865674 @default.
• W3100502483 cites W1976658982 @default.
• W3100502483 cites W1979726958 @default.
• W3100502483 cites W1999375126 @default.
• W3100502483 cites W2012818083 @default.
• W3100502483 cites W2013276624 @default.
• W3100502483 cites W2014386715 @default.
• W3100502483 cites W2028031291 @default.
• W3100502483 cites W2048525391 @default.
• W3100502483 cites W2060985684 @default.
• W3100502483 cites W2083538148 @default.
• W3100502483 cites W2097709895 @default.
• W3100502483 cites W2113170046 @default.
• W3100502483 cites W2119552229 @default.
• W3100502483 cites W2136403658 @default.
• W3100502483 cites W2138673644 @default.
• W3100502483 cites W2160177190 @default.
• W3100502483 cites W2170892587 @default.
• W3100502483 cites W2318076598 @default.
• W3100502483 cites W2319335063 @default.
• W3100502483 cites W2324650746 @default.
• W3100502483 cites W2334508015 @default.
• W3100502483 cites W2417043334 @default.
• W3100502483 cites W2490167875 @default.
• W3100502483 cites W2556579141 @default.
• W3100502483 cites W2602944657 @default.
• W3100502483 cites W2608826714 @default.
• W3100502483 cites W2729328366 @default.
• W3100502483 cites W2736721080 @default.
• W3100502483 cites W2755581937 @default.
• W3100502483 cites W2766715901 @default.
• W3100502483 cites W2778081976 @default.
• W3100502483 cites W2790555741 @default.
• W3100502483 cites W2793892668 @default.
• W3100502483 cites W2807257299 @default.
• W3100502483 cites W2888624881 @default.
• W3100502483 cites W2933292392 @default.
• W3100502483 cites W2943944372 @default.
• W3100502483 cites W2954062686 @default.
• W3100502483 cites W2963022236 @default.
• W3100502483 cites W2972706767 @default.
• W3100502483 cites W2980758585 @default.
• W3100502483 cites W3003587496 @default.
• W3100502483 cites W3005133166 @default.
• W3100502483 cites W3142903740 @default.
• W3100502483 cites W4248231685 @default.
• W3100502483 doi "https://doi.org/10.1016/j.ophtha.2020.11.012" @default.
• W3100502483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33212122" @default.
• W3100502483 hasPublicationYear "2021" @default.
• W3100502483 type Work @default.
• W3100502483 sameAs 3100502483 @default.
• W3100502483 citedByCount "25" @default.
• W3100502483 countsByYear W31005024832021 @default.
• W3100502483 countsByYear W31005024832022 @default.
• W3100502483 countsByYear W31005024832023 @default.
• W3100502483 crossrefType "journal-article" @default.
• W3100502483 hasAuthorship W3100502483A5003368090 @default.
• W3100502483 hasAuthorship W3100502483A5014220089 @default.
• W3100502483 hasAuthorship W3100502483A5017169978 @default.
• W3100502483 hasAuthorship W3100502483A5018228875 @default.
• W3100502483 hasAuthorship W3100502483A5040903099 @default.
• W3100502483 hasAuthorship W3100502483A5057095268 @default.
• W3100502483 hasConcept C103728769 @default.
• W3100502483 hasConcept C118552586 @default.
• W3100502483 hasConcept C126322002 @default.
• W3100502483 hasConcept C138496976 @default.
• W3100502483 hasConcept C156957248 @default.
• W3100502483 hasConcept C15744967 @default.
• W3100502483 hasConcept C164953862 @default.
• W3100502483 hasConcept C169900460 @default.
• W3100502483 hasConcept C1862650 @default.
• W3100502483 hasConcept C187212893 @default.
• W3100502483 hasConcept C2776694085 @default.
• W3100502483 hasConcept C2777802072 @default.
• W3100502483 hasConcept C2778242525 @default.
• W3100502483 hasConcept C2778376644 @default.
• W3100502483 hasConcept C2779234561 @default.
• W3100502483 hasConcept C2779421357 @default.
• W3100502483 hasConcept C2779918416 @default.
• W3100502483 hasConcept C44249647 @default.
• W3100502483 hasConcept C54355233 @default.
• W3100502483 hasConcept C71924100 @default.
• W3100502483 hasConcept C86803240 @default.
• W3100502483 hasConceptScore W3100502483C103728769 @default.
• W3100502483 hasConceptScore W3100502483C118552586 @default.

• next